Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $13.17

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $13.17.

Several research analysts have weighed in on the company. HC Wainwright increased their price objective on Fulcrum Therapeutics from $14.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, February 28th. Royal Bank of Canada began coverage on shares of Fulcrum Therapeutics in a research note on Wednesday, March 13th. They issued an "outperform" rating and a $14.00 price objective for the company. Piper Sandler boosted their price objective on shares of Fulcrum Therapeutics from $13.00 to $15.00 and gave the company an "overweight" rating in a report on Wednesday, February 28th. Finally, The Goldman Sachs Group increased their target price on shares of Fulcrum Therapeutics from $5.00 to $6.00 and gave the stock a "neutral" rating in a research report on Thursday, January 25th.

Fulcrum Therapeutics Stock Performance

FULC remained flat at $8.45 during trading hours on Tuesday. The company had a trading volume of 635,214 shares, compared to its average volume of 673,068. The company's 50 day simple moving average is $9.59 and its 200-day simple moving average is $6.67. Fulcrum Therapeutics has a twelve month low of $2.25 and a twelve month high of $13.70. The firm has a market cap of $523.39 million, a price-to-earnings ratio of -5.35 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.04. The company had revenue of $0.87 million during the quarter, compared to analysts' expectations of $0.65 million. Fulcrum Therapeutics had a negative return on equity of 36.65% and a negative net margin of 3,470.05%. Analysts predict that Fulcrum Therapeutics will post -1.76 EPS for the current year.

Insider Buying and Selling

In other Fulcrum Therapeutics news, VP Greg Tourangeau sold 4,884 shares of the firm's stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $11.72, for a total value of $57,240.48. Following the transaction, the vice president now directly owns 11,807 shares of the company's stock, valued at approximately $138,378.04. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of large investors have recently modified their holdings of the business. Citigroup Inc. lifted its position in shares of Fulcrum Therapeutics by 362.2% during the 2nd quarter. Citigroup Inc. now owns 7,903 shares of the company's stock worth $26,000 after buying an additional 6,193 shares during the last quarter. UBS Group AG acquired a new position in Fulcrum Therapeutics during the fourth quarter worth about $28,000. ProShare Advisors LLC bought a new position in shares of Fulcrum Therapeutics in the first quarter worth about $29,000. Tower Research Capital LLC TRC boosted its stake in shares of Fulcrum Therapeutics by 86.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,020 shares of the company's stock valued at $36,000 after purchasing an additional 5,100 shares in the last quarter. Finally, DRW Securities LLC acquired a new stake in shares of Fulcrum Therapeutics in the 2nd quarter valued at approximately $36,000. Institutional investors and hedge funds own 89.83% of the company's stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.